J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

AnaptysBio holds the No. 137 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG Therapeutics TGTX and Harmony Biosciences HRMY are among the top 5 highly rated stocks ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table ...

AnaptysBio (ANAB) stock market value increased 16.42% since last Buy rating. Financial partnership with GSK bodes favorably with hopes for added growth. Read more here.

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses at week 14, with 69% of patients achieving ...

What happenedShares of clinical-stage biotech AnaptysBio (NASDAQ: ANAB) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% ...

AnaptysBio, Inc. Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist. Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023.

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

TD Cowen analyst Joseph Thome has maintained their bullish stance on ANAB stock, giving a Buy rating today. Joseph Thome’s rating is based on several compelling factors. Despite AnaptysBio ...